Press Releases + New Year: - Any -2024202320222021202020192018201720162015201420132012201120102009 Items per page 102550 Date Title and Summary View Toggle SummaryAug 12, 2013 Galectin Therapeutics Receives FDA Fast Track Designation for GR-MD-02 for Fatty Liver Disease With Advanced Fibrosis View HTML Galectin Therapeutics Receives FDA Fast Track Designation for GR-MD-02 for Fatty Liver Disease With Advanced Fibrosis 18.1 KB Toggle SummaryAug 05, 2013 Reduction in Lung Fibrosis With the Anti-Galectin Drug GR-MD-02 Revealed in Preclinical Data Results Suggest Role for GR-MD-02 in Treating Idiopathic Pulmonary Fibrosis View HTML Reduction in Lung Fibrosis With the Anti-Galectin Drug GR-MD-02 Revealed in Preclinical Data 17.6 KB Toggle SummaryJul 24, 2013 Galectin Therapeutics Announces First Patient Dosed in Phase 1 Trial of GR-MD-02, a Potential First-in-Class Treatment for Fatty Liver Disease with Advanced Fibrosis View HTML Galectin Therapeutics Announces First Patient Dosed in Phase 1 Trial of GR-MD-02, a Potential First-in-Class Treatment for Fatty Liver Disease with Advanced Fibrosis 17.3 KB Toggle SummaryJul 01, 2013 Galectin Therapeutics Submits Fast Track Application to FDA for GR-MD-02 in Treatment of Fatty Liver Disease with Advanced Fibrosis View HTML Galectin Therapeutics Submits Fast Track Application to FDA for GR-MD-02 in Treatment of Fatty Liver Disease with Advanced Fibrosis 17.1 KB Toggle SummaryJun 21, 2013 Galectin Therapeutics Names Industry-Veteran Jack W. Callicutt Chief Financial Officer View HTML Galectin Therapeutics Names Industry-Veteran Jack W. Callicutt Chief Financial Officer 13.6 KB Toggle SummaryJun 12, 2013 Tumor Immunotherapy Efficacy Increased in Both Breast and Prostate Cancer Preclinical Models with Addition of Galectin Inhibitor -- Galectin Therapeutics and Earle A. Chiles Research Institute -- View HTML Tumor Immunotherapy Efficacy Increased in Both Breast and Prostate Cancer Preclinical Models with Addition of Galectin Inhibitor 20.3 KB Toggle SummaryMay 23, 2013 Galectin Therapeutics to Hold Conference Call to Provide Update Following Company's Annual Meeting of Shareholders -- New Phone Number for Audio Portion of Presentation View HTML Galectin Therapeutics to Hold Conference Call to Provide Update Following Company's Annual Meeting of Shareholders -- New Phone Number for Audio Portion of Presentation 12.3 KB Toggle SummaryMay 15, 2013 Galectin Therapeutics to Hold Conference Call to Provide Update Following Company's Annual Meeting of Shareholders View HTML Galectin Therapeutics to Hold Conference Call to Provide Update Following Company's Annual Meeting of Shareholders 13.5 KB Toggle SummaryMay 10, 2013 Galectin Therapeutics Reports First Quarter 2013 Financial Results View HTML Galectin Therapeutics Reports First Quarter 2013 Financial Results 15.8 KB Toggle SummaryApr 29, 2013 Galectin Inhibitors Reverse Liver Cirrhosis in Preclinical Studies - Galectin Therapeutics and Icahn School of Medicine at Mount Sinai Data Presented at the International Liver Congress 2013 - View HTML Galectin Inhibitors Reverse Liver Cirrhosis in Preclinical Studies 16.8 KB Pagination First page First Previous page Previous … Page 26 Current page 27 Page 28 Page 29 … Next page Next Last page Last
Galectin Therapeutics Receives FDA Fast Track Designation for GR-MD-02 for Fatty Liver Disease With Advanced Fibrosis 18.1 KB
Galectin Therapeutics Announces First Patient Dosed in Phase 1 Trial of GR-MD-02, a Potential First-in-Class Treatment for Fatty Liver Disease with Advanced Fibrosis 17.3 KB
Galectin Therapeutics Submits Fast Track Application to FDA for GR-MD-02 in Treatment of Fatty Liver Disease with Advanced Fibrosis 17.1 KB
Tumor Immunotherapy Efficacy Increased in Both Breast and Prostate Cancer Preclinical Models with Addition of Galectin Inhibitor 20.3 KB
Galectin Therapeutics to Hold Conference Call to Provide Update Following Company's Annual Meeting of Shareholders -- New Phone Number for Audio Portion of Presentation 12.3 KB
Galectin Therapeutics to Hold Conference Call to Provide Update Following Company's Annual Meeting of Shareholders 13.5 KB
